THROMBOPHILIA, THROMBOSIS AND ANTITHROMBOTIC THERAPY IN CANCER PATIENTS
Abstract
The clinical lection describes current views about pathogenesis of thrombotic complications in cancer patients. At the same time the risk of iatrogenic thrombophilia under the conditions of radio-, chemotherapy and hormone replacement therapy is considered. Issues concerning scientific explanation of antithrombotic prophylaxis with LMWH are given.
About the Authors
A. V. Vorobev
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
A. D. Makatsaria
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
References
1. Vorob'ev A.V. Voprosy akusherstva, ginekologii i perinatologii. 2008; 2 (7): 18-25.
2. Makatsariya A.D., Vorob’ev A.V., Chabrov A.M. Estimation value of markers of thrombophilia during chemo-and radiotherapy in cancer patients. Materials Russian Medical Forum- 2006 «Basic Science and Practice» [Znachenie otsenki markerov trombofilii pri provedenii khimio- i luchevoi terapii u onkologicheskikh bol’nykh. Materialy Rossiiskogo Meditsinskogo Foruma-2006 «Fundamental’naya nauka i praktika»]. October 18-20, 2006.
3. Makatsariya A.D., Vorob’ev A.V., Bitsadze V.O. Malignant neoplasms, thrombophilia, thrombosis. Monograph [Zlokachestvennye novoobrazovaniya, trombofiliya, trombozy. Monografiya]. Moscow. 2008; 650 s.
4. Tsyb A.F., Sushkevich G.N., Baluda M.V., Vorob’ev A.V., Chabrov A.M. Principles of prevention of thrombotic complications in patients with cancer (solid tumors). Manual for physicians. Obninsk [Printsipy profilaktiki tromboticheskikh oslozhnenii u onkologicheskikh bol’nykh (solidnye obrazovaniya). Posobie dlya vrachei]. Obninsk. 2008; 42 s.
5. Agnelli G., Bergqvist D., Cohen A. et al. Randomized doubleblind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS Study [abstract]. Blood. 2003; 102: 15a.
6. Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A., Cetin M., Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2004; 2: 1266-71.
7. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E.The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126 (3): 204-233. Erratum in: Chest. 2005 Jan; 127 (1): 415-6.
8. Bergqvist D., Agnelli G., Cohen A.T. et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N. Engl. J. Med. 2002; 346: 975-980.
9. Bona R.D. Hickcy A.D. Wallace D.M. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am. J. Clin. Oncol. 2000: 23: 71-73.
10. Borsig L., Wong R., Feramisco J. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. 2001; 98: 3352-3357.
11. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126 (3): 401-428.
12. Dolovich L., Ginsberg J.S., Douketis J.D. et al. A meta-analysis comparing low molecular weight heparins to unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med. 2000; 160: 181-188.
13. Eikelboom J.W., Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J. Thromb. Haemost. 2007; 5 (1): 255-63.
14. Falanga A. Mechanism of hypercoagulation in malignancy and during chemotherapy. Haemostasis. 1998; 28 (3): 50-60.
15. Gouin-Thibault I., Achkar A., Samama M.M. The thrombophilic state in cancer patients. Acta Haematol. 2001; 106 (1-2): 33-42.
16. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., Rustin G., Thomas M., Quigley M., Williamson R.C. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 2004; 22: 1944-8.
17. Kearon C., Ginsberg J.S., Kovacs M. et al. Comparison of low-intensity warfarin therapy with conventional intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N. Engl. J. Med. 2003; 349:631-639.
18. Kleber F.X., Flosbach C.W., Koppenhagen K. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III/IV (PRINCE II study). Circulation. 1999; 100 (1): 1-619.
19. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., Prandoni P., Bos M.M., Richel D.J., van T.G., Buller H.R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005; 23: 2130-5.
20. Lee A.Y., Levine M.N., Baker R.I. et al. Lowmolecular-weight heparin versus a oumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2003; 349: 146-153.
21. Levine M.N., Lee A.Y. Treatment of venous thrombosis in the cancer patient. Acta Haematol. 2001; 106 (1-2): 81-87.
22. Ludwig R.J., Alban S., Bistrian R., Boehncke W.H., Kaufmann R., Henschler R., Gille J. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb. Haemost. 2006; 95: 535-40.
23. Monreal M., Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol. 2001; 106 (1-2): 69-72.
24. Nasir F.A., Patel H.K., Scully M.F., Fareed J., Lemoine N.R., Kakkar A.K. The low molecular weight heparins dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumour model (abstract 2993). Blood. 2003; 102.
25. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch. Intern. Med. 2000; 160: 3415-20.
26. Shaker A. Mousa. Low-Molecular-Weight Heparin in Thrombosis and Cancer. Seminars in thrombosis and hemostasis. 2004; 30: 25-29.
27. Vorobiev A.V., Makatsaria A.D., Chabrov A.M. Thrombophilia markers in cancer patients during chemotherapy and radiation therapy. Pathophysiology of haemostasis and thrombosis. 2006; 35 (1-2): A20.
28. von Tempelhoff G.F., Harenberg J., Niemann F. et al. Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int. J. Oncol. 2000; 16: 815-82.
29.
30.
Review
For citations:
Vorobev A.V., Makatsaria A.D. THROMBOPHILIA, THROMBOSIS AND ANTITHROMBOTIC THERAPY IN CANCER PATIENTS. Obstetrics, Gynecology and Reproduction. 2014;8(2):139-148. (In Russ.)
Views:
737
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
